Extracellular protein sensitizes ovarian cancer cells to chemotherapy

Dec 10, 2007

Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy. The research, published by Cell Press in the December issue of Cancer Cell, helps to explain why many patients develop resistance to the taxane class of drugs and may lead to improved treatment of ovarian cancer.

Cancer cells divide rapidly and undergo extensive microtubule-driven restructuring as they proliferate. Taxanes, such as paclitaxel (Taxol), interfere with the dynamic growth of microtubules by directly binding to them and making them more stable and, as a result, disrupt the normal process of cell division. Paclitaxel has been used extensively to treat lung, ovarian and breast cancers but drug resistance limits the clinical usefulness of this drug to only about half of breast or ovarian cancer patients.

Although it is clear that taxane resistance is associated with a loss of stable microtubules and that microtubule stability can be influenced by signals from the extracellular matrix (ECM), a role for ECM proteins in the modulation of paclitaxel sensitivity has not been established. To explore the connection between regulation of microtubules and taxane resistance, Dr. James D. Brenton from the Cancer Research UK Cambridge Research Institute in Cambridge, England and colleagues performed an extensive examination of ovarian cancer cell lines that were sensitive or resistant to paclitaxel.

The researchers found that the ECM protein, transforming growth factor beta induced (TGFBI), was significantly reduced in paclitaxel-resistant cells. Importantly, TGFBI mediated sensitization to paclitaxel and loss of TGFBI was sufficient to induce paclitaxel resistance. TGFBI induced microtubule stabilization that was dependent on integrin-mediated FAK and Rho signaling. Further, analysis of ovarian cancer samples taken after treatment with paclitaxel revealed that paclitaxel-induced cell death was associated with high levels of TGFBI expression.

These results identify TGFBI as an ECM protein that induces microtubule stability and modulates sensitivity to paclitaxel in ovarian cell lines and in patients receiving paclitaxel therapy. “Our findings have potentially significant clinical applications as TGFBI protein expression is lost in one third of primary ovarian and lung cancers and FAK is low or absent in one-third of ovarian cancer patients,” explains Dr. Brenton. “It is possible that TGFBI could be used as a biomarker for selecting patients likely to respond to taxane therapy. In addition, proteins that activate TGFBI or mimic its action may be an effective strategy for modulating the response to widely used drugs like paclitaxel or docetaxel.”

Source: Cell Press

Explore further: New genetic test may change how brain cancer is treated, researchers say

add to favorites email to friend print save as pdf

Related Stories

Why conspiracy theorists won't give up on MH17 and MH370

19 minutes ago

A huge criminal investigation is underway in the Netherlands, following the downing of flight MH17. Ten Dutch prosecutors and 200 policemen are involved in collecting evidence to present at the International Criminal Court in the Hague. The inv ...

Twitter tries to block images of Foley killing

28 minutes ago

Twitter is trying to block the spread of gruesome images of the beheading of journalist James Foley by Islamic State militants, while a movement to deny his killers the publicity they crave is also gaining ...

New generation is happy for employers to monitor them on social media

29 minutes ago

Will employers in the future watch what their staff get up to on social media? Allowing bosses or would-be employers a snoop around social media pages is a growing trend in the US, and now a new report from PricewaterhouseCoopers and the Said Business School suggest ...

Researchers discover new strategy germs use to invade cells

49 minutes ago

The hospital germ Pseudomonas aeruginosa wraps itself into the membrane of human cells: A team led by Dr. Thorsten Eierhoff and Junior Professor Dr. Winfried Römer from the Institute of Biology II, members of the Cluster ...

Recommended for you

Understanding your kidney tumor in 3D

2 hours ago

Most patients rely on their doctors to decipher the black, white and gray images on their CT scans. But what if a patient could instead hold a 3D model made from the CT image in his hands? Suddenly, the picture ...

Biomarker in aggressive breast cancer identified

16 hours ago

Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, ...

MRI better detects recurrent breast cancer

17 hours ago

(HealthDay)—Single-screening breast magnetic resonance imaging (MRI) detects 18.1 additional cancers after negative findings with mammography and ultrasonography (US) per 1,000 women with a history of breast ...

User comments : 0